Body composition · Fat loss Rx · Prescription required

AOD-9604.

Anti-Obesity Drug 9604

A modified GH fragment (residues 176–191) that mobilizes fat without affecting blood sugar or growth. The recomposition tool for stubborn adipose without the GH-axis stack.

From $200 / month
MW 1815.1 Molecular weightThe mass of one molecule in g/mol. A small modified fragment; fully characterized.
Sequence 16 aa Peptide chain length16 amino acids — the C-terminal lipolytic region (176–191) of full-length growth hormone, modified for stability.
Route Sub-Q How you take itSubcutaneous: under the skin. Same technique as a GLP-1 or insulin pen.
Cycle 8–12 wk Cycle lengthTypical 12-week loading cycle, daily AM dosing. Followed by an off-cycle to reassess.
Discovered 1990s First isolatedAOD-9604 was developed in the 1990s by Metabolic Pharmaceuticals as a fat-loss derivative of GH.
Begin your protocol Free assessment · No card · Rx required
AOD-9604 Body composition
MW 1815.1 Length 16 aa Route Sub-Q Cycle 12 wk
Begin →
01 The case

Lipolysis without the rest.

AOD-9604 is the C-terminal fragment of growth hormone, residues 176–191, with a modification that improves stability. The interesting feature is what it does and what it doesn't: lipolysis without the IGF-1 elevation, glucose interference, or anabolic effects of full-length GH.

Mechanism is beta-3 adrenergic activation in adipocytes. The fragment mobilizes stored fat — especially visceral — and pushes it into the oxidation pathway. There's no insulin sensitivity penalty; in some models there's a modest improvement.

It is the recomposition tool for members with stubborn adipose who don't want or need the GH axis stack. It also has preclinical cartilage benefits, though the lipolytic application is what it's prescribed for.

02 Mechanism

Where it acts.

Six effects of one targeted action — beta-3 adrenergic activation in adipocytes.

AOD-9604 C₂₆₈H₄₀₈N₇₂O₈₁S
⌬ Beta-3 adrenergic Activates lipolysis pathway in adipocytes
⊖ Targeted lipolysis Mobilizes stored adipose for oxidation
◐ Glucose-neutral No insulin sensitivity interference
∿ No IGF-1 elevation Distinct from full-length GH effect profile
↗ Visceral preference Targets the metabolically active fat depot
⚛ Cartilage benefits Preclinical evidence for joint support
03 Evidence

A focused fragment.

AOD-9604 is narrower in scope than full-length GH and that's the point. Here's what the literature establishes.

176-191

the GH C-terminus fragment — the lipolytic region

Peptide chemistry
Lipolysis-only

no anabolic, IGF-1, or glucose effect

Mechanism studies
12 wk

typical evaluation cycle for body composition change

Clinical observation
0

interference with insulin sensitivity in published reports

Safety profile
04 Who it's for

Built for recomposition.

Most often prescribed for stubborn adipose, especially visceral. A narrow tool — not a longevity foundation.

⊖

Stubborn adipose

Targeted lipolysis where the body doesn't volunteer.

◐

Visceral fat

Preferential mobilization of metabolically active depot.

∿

Post-GLP recomp

Body-composition tuning after weight loss.

⚛

Cartilage support

Preclinical evidence — adjunct, not primary indication.

↗

Glucose-neutral

Useful when GH-axis stacks are not appropriate.

⌒

Recovery layer

Adjunct in heavier recovery protocols.

05 Protocol

A sample protocol.

AOD-9604 is dosed daily in the morning, fasted, for a 12-week cycle. Your physician sets the cadence.

Sample parameters

Illustrative
Route
Subcutaneous injection
Dose
250–300 mcg
Frequency
Daily (morning)
Cycle
8–12 weeks
Storage
Refrigerated, light-protected

Fasted morning dose. AOD-9604 is taken on an empty stomach to align with the lipolytic window. Compounded fresh by a 503A pharmacy to USP 797 sterile standards.

The cadence

Your week 7 days · daily AM
MAM
TAM
WAM
TAM
FAM
SAM
SAM
Your cycle 12 wk · continuous (8 shown)
1on
2on
3on
4on
5on
6on
7on
8on
Fasted · ~3 min Site rotates: abdomen · thigh
06 What arrives

In the box.

Compounded fresh, cold-chain shipped overnight from a U.S.-based 503A pharmacy. Everything you need to start the same week.

⚲
Compounded vials

Multi-dose vial · USP 797 sterile · beyond-use date printed.

⊕
Injection supplies

Insulin syringes, alcohol pads, bacteriostatic water for reconstitution.

❄
Cold-pack shipping

Insulated overnight delivery with ice pack. Tracked door to door.

📖
Step-by-step guide

Reconstitution, dosing math, injection technique, sharps disposal.

07 Often paired with

Stacks that work.

AOD-9604 is narrow by design. When stacked, it's usually with the GH axis or a recovery foundation.

Sermorelin

Sermorelin builds lean mass while AOD-9604 mobilizes adipose — complementary signals.

GH axisFrom $195/mo →
CJC-1295 + Ipa

The strong recomposition stack — lean signal plus targeted lipolysis.

Recomp stackFrom $250/mo →
BPC-157

Tissue repair foundation under the metabolic load.

RecoveryFrom $225/mo →
08 Safety

Side effects, fine print, responsibility.

AOD-9604 has a narrow effect profile and a clean safety reputation. Here's what to expect.

✓

What to expect

  • 01Mild injection-site reactions — redness, light bruising. The most common report.
  • 02No glucose interference — the defining feature — insulin sensitivity is preserved.
  • 03Body composition changes in 8–12 wk — the targeted endpoint.
  • 04No anabolic effect — lean mass is not directly built — pair with GH axis if that's the goal.
!

Not for

  • 01Pregnancy or breastfeeding. Insufficient safety data.
  • 02Active malignancy. Adipocyte metabolic stimulation requires oncologic oversight.
  • 03Severe cardiovascular disease. Discuss adrenergic activation with your physician.
  • 04Use without oversight. Always under a licensed physician's supervision.

Compounded AOD-9604 is not an FDA-approved drug product. It is dispensed by a licensed 503A compounding pharmacy under a prescription written by a U.S.-licensed physician for individual investigational and off-label use under provider supervision. Statements on this page have not been evaluated by the FDA. Individual results vary.

09 Questions

Frequently asked.

What is AOD-9604?+

AOD-9604 is the C-terminal fragment of growth hormone (residues 176–191) with a stability modification. It retains the lipolytic effect of GH without the IGF-1 elevation, glucose interference, or anabolic effects.

How is it different from full GH or Sermorelin?+

Full GH and Sermorelin engage the entire GH axis — lean mass, IGF-1, glucose. AOD-9604 isolates the lipolytic action. It's narrower; that's the design.

Does it affect blood sugar?+

No. The fragment was specifically engineered to drop the glucose-interfering region of GH. In published reports there's no insulin sensitivity penalty.

How long until I see fat loss?+

Body composition changes typically emerge over 8–12 weeks. It is not a same-week effect, and it works best alongside diet and training inputs.

Can I stack it?+

Yes — common pairings include Sermorelin (GH axis), CJC + Ipa (lean signal + lipolysis), and BPC-157 (recovery foundation). Your physician designs the stack.

Side effects?+

Mild injection-site reactions are the most common. No glucose or anabolic effects. No serious adverse effects established in the published literature to date.

Begin Ten minutes of intake

Begin your AOD-9604 protocol.

Free assessment. A board-certified U.S. physician on the prescription. Bloodwork only if your protocol calls for it. Compounded fresh and cold-chain shipped overnight.

Start your intake Free · No card required · Rx required to ship

Other compounds in the roster.

All 8 therapies →
Sermorelin

GHRH analog. Sleep depth, lean mass, recovery — pulses your own GH at night.

From $195/mo CJC-1295 + Ipa

Long-acting GHRH paired with a selective GH secretagogue. Stronger pulse, no cortisol spike.

From $250/mo BPC-157

15-aa fragment from gastric juice. Tendon, ligament, gut. The repair signal stack-mate.

From $225/mo

Deeper guides on AOD-9604.

All guides →